Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice

Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena-de-Cea, Álvaro; Rodríguez-Osorio, Iria; Pernas-Souto, Berta; Delgado-Blanco, Manuel; Pertega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles.
Rev. esp. quimioter ; 32(2): 137-144, abr. 2019. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-182815

Documentos relacionados

  1. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
  2. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
  3. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
  4. Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin.
  5. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
  6. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
  7. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
  8. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
  9. The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.
  10. Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.